Results 41 to 50 of about 5,655,373 (303)
Farewell to the term ‘non-alcoholic fatty liver disease’
, 2023 After years of debate, the nomenclature non-alcoholic fatty liver disease (NAFLD) has been changed to metabolic dysfunction–associated steatotic liver disease, or MASLD (figure 1).
Mortimore, G.
core
Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway. [PDF]
PLoS ONE, 2016 Non-alcoholic fatty liver disease is one of the most important causes of liver-related morbidity in children. In non-alcoholic fatty liver disease, the activation of liver resident macrophage pool is a central event in the progression of liver injury ...
Guido Carpino +10 more
doaj +1 more source
World Journal of Hepatology, 2012 Alcohol use disorders affect millions of individuals worldwide. Alcohol consumption is directly associated with liver disease mortality and accounts for elevated social and economic costs. Alcoholic liver disease (ALD) may take the form of acute involvement (alcoholic hepatitis) or chronic liver disease (steatosis, steatohepatitis, fibrosis and ...
Radan, Bruha +2 more
openaire +2 more sources
Design and analysis strategies for robust microbiome ageing research
FEBS Letters, EarlyView.The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik +5 more
wiley +1 more source
Structure‐forward targeting of claudins with synthetic binders
FEBS Letters, EarlyView.Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley +1 more source
Therapeutic Advances in Gastroenterology, 2021 Introduction: The optimal approach to screening and risk stratification for non-alcoholic fatty liver disease is challenging given disease burden and variable progression. The aim of this study was to assess primary care physician and referring physician
Naba Saeed +6 more
doaj +1 more source
Liver transplantation for alcoholic liver disease [PDF]
Clinical Liver Disease, 2013 Alcoholism is a disease of remission and relapse. A lapse in abstinence tends to be viewed as a failure to commit to abstinence, and an acknowledged relapse may lead to the patient's removal from the liver transplant list; however, such a relapse may actually offer insight into alcoholism.
Patrizia, Burra, Michael R, Lucey
openaire +2 more sources
A Review of the Effects of Omega-3 and Omega-6 on Alcoholic and Non-Alcoholic Fatty Liver [PDF]
Non-alcoholic fatty liver disease (NAFLD) is characterized by fat accumulation in the liver not caused by excessive alcohol consumption. In contrast, alcoholic liver disease (ALD) is directly caused by it.
Darvishi, Mohammad +6 more
core +1 more source
Liver organoids: modelling complexity in homeostasis and disease
FEBS Letters, EarlyView.Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley +1 more source
Diagnosis of Non-alcoholic fatty liver disease
Journal of Pathology of Nepal, 2016 Non Alcoholic Fatty Liver Disease is the deposition of fat in liver in absence of excessive of alcohol consumption. Non Alcoholic Fatty Liver Disease ranges from simple steatosis to Nonalcoholic steatohepatitis and cirrhosis.
Geetika K.C.
doaj +1 more source